SEC Form 4
Opus Genetics, Inc. (IRD) insider trading
In the 12 months to Oct 26, 2026, 2 IRD insiders reported open-market sales of $18.8M across 3 filings; one director bought $323.7K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $18.8M
- 3 filings · 2 insiders
- Open-market purchases
- $323.7K
- 1 filing · Cam Gallagher, Director
Who traded IRD, and when
- Purchase
- Sale
IRD daily close from Oct 27, 2025 to Oct 26, 2026, between $1.74 and $6.07, last $3.35. 3 sale and 1 purchase filings by 3 insiders, marked at their filing dates. Foundation Fighting Blindness Retinal Degeneration Fund, Director: sold $10.2M across 2 filings, first filed May 20, 2026, last Oct 2, 2026. Foundation Fighting Blindness, Inc., Director: sold $8.6M across 1 filing, first filed Dec 11, 2025, last Dec 11, 2025. Cam Gallagher, Director: bought $323.7K across 1 filing, first filed Dec 31, 2025, last Dec 31, 2025.
Largest mark · tap a row for others
Foundation Fighting Blindness, Inc. · Director
Sale $8,600,000
4,000,000 shares at $2.15 avg
Filed Dec 11, 2025 · traded Dec 9
Close on filing date $2.44
Foundation Fighting Blindness Retinal Degeneration Fund · Director
Director
$10.2M soldFoundation Fighting Blindness, Inc. · Director
Director
$8.6M soldCam Gallagher · Director
Director
$323.7K boughtOpen-market trades
4 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | Director | $10.2M | — | 2 | — | |
| Foundation Fighting Blindness, Inc. | Director | $8.6M | — | 1 | — | |
| Cam Gallagher | Director | — | $323.7K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Foundation Fighting Blindness Retinal Degeneration Fund Director | Sale | 556,000 | $4.96 | $2.8M | 3,236,171 | |
traded | Foundation Fighting Blindness Retinal Degeneration Fund Director | Sale | 1,700,000 | $4.35 | $7.4M | 3,792,171 | |
traded | Cam Gallagher Director | Purchase | 164,000 | $1.97 | $323.7K | Multiple accounts | |
traded | Foundation Fighting Blindness, Inc. Director | Sale | 4,000,000 | $2.15 | $8.6M | 5,492,171 |
GET /stocks/filings/vX/form-4?tickers=IRD&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"IRD",
"OCUP"
],
"issuer_cik": "0001228627",
"owner_cik": "0002042266",
"accession_number": "0002042266-26-000002",
"form_type": "4",
"filing_date": "2026-10-02",
"period_of_report": "2026-09-30",
"issuer_name": "Opus Genetics, Inc.",
"issuer_trading_symbol": "IRD",
"owner_name": "Foundation Fighting Blindness Retinal Degeneration Fund",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-30",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 556000,
"transaction_price_per_share": 4.9568,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 3236171,
"transaction_value": 2755980.8000000003,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction was executed in multiple trades at prices ranging from $4.95 to $5.29. The price reported in Column 4 is a weighted average price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."
},
{
"id": "F2",
"description": "Foundation Fighting Blindness, Inc. (\"FFB\") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund (\"RDF\") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold."
}
],
"remarks": "For purposes of Section 16 of the Exchange Act of 1934, as amended, the Reporting Persons may be deemed a director by deputization of Issuer by virtue of the fact that Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to serve on the board of directors of Issuer and Dr. Graves is the chair of the board of directors of RDF and a member of the board of directors of FFB and Dr. Bennett is a member of the board of directors of RDF."
},
{
"tickers": [
"IRD",
"OCUP"
],
"issuer_cik": "0001228627",
"owner_cik": "0002042532",
"accession_number": "0002042266-26-000002",
"form_type": "4",
"filing_date": "2026-10-02",
"period_of_report": "2026-09-30",
"issuer_name": "Opus Genetics, Inc.",
"issuer_trading_symbol": "IRD",
"owner_name": "Foundation Fighting Blindness, Inc.",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-30",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 556000,
"transaction_price_per_share": 4.9568,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 3236171,
"transaction_value": 2755980.8000000003,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This transaction was executed in multiple trades at prices ranging from $4.95 to $5.29. The price reported in Column 4 is a weighted average price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."
},
{
"id": "F2",
"description": "Foundation Fighting Blindness, Inc. (\"FFB\") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund (\"RDF\") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold."
}
],
"remarks": "For purposes of Section 16 of the Exchange Act of 1934, as amended, the Reporting Persons may be deemed a director by deputization of Issuer by virtue of the fact that Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to serve on the board of directors of Issuer and Dr. Graves is the chair of the board of directors of RDF and a member of the board of directors of FFB and Dr. Bennett is a member of the board of directors of RDF."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 41 records
- Option exercises2 records
- Tax withholding5 records
- Tax withholding (sold to cover)15 records
- Grants and awards19 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Opus Genetics, Inc.'s CEO sold stock?
No. George Magrath (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is IRD’s insider data?
These are IRD Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track IRD insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for IRD every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.